随机临床试验中的替代终点和中间终点：目标是什么？
Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?
机构信息
Biometric Research Program, National Cancer Institute, Bethesda, Maryland.
出版信息
Clin Cancer Res. 2018 May 15;24(10):2239-2240. doi: 10.1158/1078-0432.CCR-18-0183. Epub 2018 Feb 12.
Abstract
Establishing trial-level surrogacy of an intermediate endpoint for predicting survival benefit in future trials is extremely challenging because of the extrapolations required, but there are other useful drug development and patient management applications of intermediate endpoints. .
摘要
建立中间终点的试验级替代指标来预测未来试验中的生存获益极具挑战性，因为需要进行外推，但中间终点在药物开发和患者管理方面还有其他有用的应用。
Zotero 插件